Pharmamarketeer

Latest articles

Sanofi announces positive phase 3 data for Dupixent

Sanofi has announced positive phase 3 data showing that nearly three times as many Dupixent patients experienced lower rates of itching and skin lesions at 24 weeks compared to the placebo. Detailed positive results...

Medhc-fases-banner
Advertentie(s)